If you’re considering treatment for opioid use disorder (OUD), your doctor may recommend Sublocade. It’s prescribed as part of a complete treatment program to manage opioid addiction in adults with ...

Sublocade (buprenorphine) is a brand-name prescription medication. It’s approved by the Food and Drug Administration (FDA) to treat moderate to severe opioid use disorder in people who received ...

Sublocade (buprenorphine) and Vivitrol (naltrexone) are prescription drugs used to treat opioid use disorder. Vivitrol is also prescribed for alcohol use disorder. Both drugs come as an injection ...

Sublocade (buprenorphine) is a brand-name prescription medication. The Food and Drug Administration (FDA) has approved it to treat opioid use disorder in adults, as part of a complete treatment ...

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm tolerability. 1 ...

Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...

The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...

Sublocade should be used as part of a complete treatment program that includes counseling and psychosocial support. Indivior announced that the Food and Drug Administration (FDA) has approved ...

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. Let ...

The CEO highlighted that 2024 ended with SUBLOCADE achieving 20% net revenue growth despite challenges, including competition ...

Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) These FDA ...